The National Company Law Tribunal (NCLT), Bengaluru Bench, has sanctioned the Scheme of Amalgamation between Shilpa Therapeutics Private Limited and its parent company, Shilpa Medicare Limited. As the transferor is a wholly-owned subsidiary, no new shares will be issued, and the existing share capital of the subsidiary will stand cancelled. The merger, with an appointed date of April 1, 2023, aims to streamline corporate structure and integrate operations. The company is now in the process of filing the certified order with the Registrar of Companies to make the merger effective.

Shilpa Medicare's subsidiary, Shilpa Biologicals, has entered into a strategic licensing agreement with SteinCares to commercialize a biosimilar across Latin America. SteinCares will hold exclusive rights to register and distribute the product across 30 countries in the region, while Shilpa will handle development and long-term manufacturing from its Dharwad facility. This agreement marks Shilpa Biologicals' first entry into the Latin American market, a significant step in its global biosimilar expansion. The partnership leverages SteinCares' 45 years of regional expertise to provide cost-effective specialty treatments.

Shilpa Medicare has entered into a strategic partnership with Swiss biotech firm NXI Therapeutics AG for the development and commercial manufacturing of a New Chemical Entity (NCE) targeting autoimmune disorders. This marks the company's third major international mandate in recent months, reinforcing its growing presence in the global CDMO market. The agreement covers the entire product lifecycle, including CMC development, clinical supply, and long-term commercial manufacturing. While financial terms remain confidential, the deal includes milestone-linked expansion potential and strengthens Shilpa's high-value innovation pipeline.

Shilpa Medicare has entered into a binding agreement with Switzerland's NXI Therapeutics AG for the development and supply of a New Chemical Entity (NCE) targeting autoimmune disorders. This marks the company's third major international mandate in recent months, reinforcing its transition into a high-value CDMO partner. The collaboration covers the full product lifecycle, including CMC development, clinical studies, and long-term commercial GMP manufacturing. While specific financial terms are confidential, the deal includes milestone-linked expansion potential and enhances long-term revenue visibility.

Shilpa Medicare reported its highest-ever quarterly performance with revenue reaching ₹411 crores, a 28% YoY increase, and EBITDA growing 41% to ₹115 crores. The company's adjusted PAT for the first nine months of FY26 at ₹146 crores has already nearly doubled the full-year PAT of FY25. Growth is primarily driven by a 50% surge in the formulations business and strong traction in the European market. Management is shifting focus from heavy R&D investment to execution, with significant product launches like Rotigotine and NorUDCA expected to drive future ROCE.

Shilpa Medicare reported a robust performance for Q3 FY26, with consolidated revenue growing 28.3% YoY to ₹409.73 crore. Net profit for the quarter rose significantly by 40.3% YoY to ₹44.58 crore, driven by strong operational execution despite a marginal 1.2% growth on a sequential basis. A major strategic milestone was achieved with the filing of the Rotigotine Transdermal System, the company's first transdermal patch ANDA, with the USFDA. The company also reconstituted its Audit Committee, inducting Mr. Ashraf Allam as an independent director.

Shilpa Medicare reported its strongest-ever quarterly performance in Q3 FY26, with revenue growing 28% YoY to ₹411 crore and adjusted PAT jumping 72% to ₹55 crore. The growth was driven by a 50% surge in the Formulations segment and robust traction in Biologics, while EBITDA margins expanded by 200 bps to 28%. For the 9M FY26 period, the company has already surpassed its full-year FY25 PAT, reaching ₹146 crore. Management highlighted significant progress in high-value product launches, including NorUDCA for NAFLD in India and EU approval for the Rotigotine patch.

Shilpa Medicare reported a robust performance for Q3 FY26, with consolidated revenue growing 28% YoY to ₹410.54 Cr. Consolidated Net Profit surged 40% YoY to ₹44.58 Cr, even after accounting for an exceptional loss of ₹12.86 Cr. For the nine-month period, the company's consolidated PAT more than doubled to ₹135.53 Cr compared to ₹63.78 Cr in the previous year. The board also strengthened its governance by inducting Mr. Ashraf Allam into the Audit Committee.

Shilpa Medicare reported a strong performance for the quarter ended December 31, 2025, with consolidated revenue from operations growing 28.3% YoY to ₹409.73 crore. Consolidated net profit for the quarter stood at ₹44.58 crore, a significant jump from ₹31.78 crore in the same period last year. The company faced exceptional losses of ₹12.86 crore on a consolidated basis, primarily due to impairment provisions and adjustments related to new labor codes. Despite these one-off items, the operational growth remains robust, driven by both sales and service income.

Shilpa Medicare reported a robust performance for Q3 FY26, with consolidated revenue from operations growing 28.3% YoY to ₹409.73 crore. Net profit for the quarter increased by 40.3% YoY to ₹44.58 crore, despite an exceptional loss of ₹12.86 crore. For the nine-month period ending December 2025, the company's consolidated PAT more than doubled to ₹135.53 crore from ₹63.78 crore in the previous year. The board also inducted Mr. Ashraf Allam into the Audit Committee as an Independent Director.

Shilpa Biologicals, a subsidiary of Shilpa Medicare, has achieved a major milestone with the US FDA granting Orphan Drug Designation (ODD) to its monoclonal antibody for treating rare blood cancers. The designation covers Essential Thrombocythemia (ET) and Polycythemia Vera (PV), conditions with high unmet medical needs. This regulatory status provides the company with development support, tax credits, and potential market exclusivity upon final approval. The company is now progressing toward IND-enabling studies to initiate first-in-human clinical trials.